AI Article Synopsis
- A new method is introduced for detecting PCA3, a urinary biomarker for prostate cancer, using a personal glucose meter (PGM) for quantitative analysis.
- The method uses magnetic beads for specific hybridization of target nucleic acids and alkaline phosphatase to convert D-glucose-1-phosphate into D-glucose, amplifying the detection signal.
- This genoassay shows high sensitivity, a range of 5 to 100 pM, and a limit of detection at 5 pM, allowing for easy point-of-care testing without needing complex lab equipment.
Article Abstract
A personal glucose meter (PGM)-based method for quantitative detection of a urinary nucleic acid biomarker in prostate cancer screening, the so-called PCA3, is reported herein. A sandwich-type genoassay is conducted on magnetic beads to collect the target from the sample by specific hybridization, making the assay appropriate for PCA3 detection in biological fluids. The success of the method hinges on the use of alkaline phosphatase (ALP) to link the amount of nucleic acid biomarker to the generation of glucose. In particular, specifically attached ALP molecules hydrolyze D-glucose-1-phosphate into D-glucose, thus enabling the amplification of the recorded signal on the personal glucose meter. The developed genoassay exhibits good sensitivity (3.3 ± 0.2 mg glucose dL pM) for PCA3, with a dynamic range of 5 to 100 pM and a quantification limit of 5 pM. Likewise, it facilitates point-of-care testing of nucleic acid biomarkers by using off-the-shelf PGM instead of complex instrumentation involved in traditional laboratory-based tests.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583019 | PMC |
| http://dx.doi.org/10.3390/s20195514 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!